Author Archives: Darren

The group would like to thank all key workers in these difficult times for there help support and determination to get things done.

New Children’s ESN in Scotland health board

A new children’s epilepsy specialist nurse (ESN) has been appointed by the NHS Dumfries and Galloway health board. For years’ this was reportedly the only mainland health board without a specialist paediatric ESN in Scotland.
Sarah Gemmel has taken the new role of epilepsy and complex needs lead at the health board. The charity Epilepsy Scotland and families of children with epilepsy have campaigned for this appointment.
Sarah Gemmel said I am excited to take on this new role that will provide the essential service for offering practical and emotional support to children and families in Dumfries and Galloway.

Seizure prediction device could give hour’s notice

A wearable device has been developed that can predict a seizure an hour before onset with potentially 97% accuracy.
The device called Epiness has been developed by Israeli researchers at Ben-Gurion University of the Negev. The device uses machine learning algorithms and EEG based monitoring of the brain activity.
The product which is not available to buy yet is due to undergo clinical trials later this year.
In development and testing large EEG datasets were used, and the prediction performance reached 97% accuracy.
For people with epilepsy whose seizures are not controlled an effective prediction device could help reduce injuries and increase independence.
Source Epilepsy Action

Five Year Old “hero” helps mum during seizure

A five year-old girl has been called a “hero” for getting help when her mum had a seizure.
Lisa Wainwright had a seizure out of the blue at her Derbyshire home when she was alone with her daughters Esme, five and Amelia, two.
When the seizure started Esme handed her mum the phone who then typed a message to her husband Ash, When Ash rang back Esme picked up the phone and told him what had happened. She unlocked the door when he came home.
He saw that she had covered her mum over with a blanket and had stopped her little sister from crying by setting up her tablet for entertainment.
The 34 year old mum of two called Esme a “hero” and a “superstar” and said she’s really proud of Esme.

Long Term VNS effectiveness

A new study from the journal Epilepsy & Behaviour suggests that vagul nerve stimulation ( VNS) is effective and safe for children in the long term.

Study authors Dilek Yalnizoglu and colleagues investigated 58 children in Turkey with hard to treat epilepsy who had VNS put in between 1997 and 2018. The average follow up was around six years, although it ranged from three months to 20 years.

The researchers found that just under half of the children had their seizures reduced by at least half, with three children becoming seizure free. The effectiveness of the VNS wasn’t affected by the cause of the epilepsy, how long they had had epilepsy or what age they had the VNS put in. However, it worked better in the children who had focal seizures. more than half of the children also had a better quality of life.

The most common side-effects were voice change and a pins and needles sensation.

Epilepsy Support For You

For some of us, epilepsy can be an isolating condition which can make us feel lonely and misunderstood. But there are actually many people in the UK and around the world with the condition. One of Epilepsy Action’s roles is bringing people together to share their knowledge and experiences and talk to other going through similar situations.

We know that many of you take comfort from meeting others affected by epilepsy through our branches and coffee and chat groups. As we aren’t currently able to offer that support, our virtual groups are a great way of connecting with others.

You can find more information on all our support services at you can also get more details by calling us on 01132108800.
Source Epilepsy Action

New therapy could stop seizures in rare epilepsies

A type of gene therapy could help those with rare forms of childhood epilepsy, including Dravet Syndrome. This breakthrough could lead to treatments for developmental epileptic encephalopathies developing from a single genetic mutation. Encephalopathy is when brain function is impaired by a condition such as viral infection or toxins in the blood. Within the brain the gene SCN8A controls a sodium channel that allows neurons to transmit an electric signal. Sodium channels are membranes in the brain responsible for allowing neurons to communicate. Mutated versions of the SCN8A gene can cause these channels to become hyperactive and bring on repeated seizures. This condition is knowen as SCN8A-Related Epilepsy and average inset age is just four months old.
Miriam Meisler is a professor of neurology at U-M Medical School in the US. Her team have studied the condition for many years and are trying new therapies to treat this epilepsy. She says approximately half of these people affected are severely impaired and cannot walk or talk.
The breakthrough using antisense oligonucleotide (ASO’s) which are short DNA or Ribonucleic acid (RNA) molecules enabled researchers to control how much genes communicate with the body. RNA acts as a messenger carrying information from the DNA about specific proteins. By controlling the amount of RNA expressed by the mutated genes, the team found they could reduce its effects on the body.
By using mice with the same mutated gene they were able to develop an off switch for the gene by activating the ASOs. The effect was dramatic and unambiguous says Meisler. We had a four-fold increase in lifespan with added effects of repeated treatments. There was no evidence of low-level seizure activity in the treated mice.
The level of RNA expressed was reduced by half after the treatment. It was also discovered that the technique was effective against other types of epilepsies including Dravet Syndrome.
The team is now carrying out further testing to see how effective they are against other seizure types. The results are published in Annals of Neurology. For the full study visit:

EU funds project to develop nanodevices against epilepsy

Nanotechnology is being studied to develop revolutionary treatments for neurological conditions such as epilepsy. This technology involves the study and development of devices that could control
extremely small objects such as atoms and molecules. Researchers hope that these nanodevices could
could be used as brain implants that control the activity of neurons, reducing or stopping seizures.
The IN-FET project (Ion Neuromodulation Epilepsy Treatment) was launched in January 2020 and has recently been given a 3 Million Euro grant from the European Union. With the approved funding, the will be looking at using nanotechnology and looking at ions such as magnesium, potassium and calcium. These are the chemicals which allow neurons to communicate. Nanodevices could look at and control these ions, and importantly, their concentration. From here it should be possible to change their cell activity, meaning activating or turning off certain neurons. In epilepsy it’s the flow of ions that leads to the burst of electrical activity in the neurons, leading to seizures. Here the nanodevices would act as an ion trap, so they no longer excite the cells, preventing such seizures. Professor Michele Giugliano, is the director of the Neuronal Dynamics Lab at SISSA (Scuola Internazionale Superiore di Studi Avanzati) in Italy. She says Epilepsy is one of the most common neurological conditions affecting 50 Million people worldwide. Drug treatment is a widespread approach to fight it but for many people medication is no help. Epilepsy drugs prove ineffective with the condition. Drug resistance amongst adults ranges between 30% and 40%.
The European project brings together experts in nanoengineering information technology and neurobiology and is funded by the European programme Future Emerging Technologies (FET) Open. The initiative will involve IBM Research, Multi Channel Systems, the Universities of Geneva and Sheffield and the Italian Inter-University Consortium for Nanoelectronics, amongst other parties. The aim of the group will be to develop implantable devices that can alter the concentration of these microscopic ions. These devices will be able to measure the electrical activity of neurons and actively work to correct it.
Todays experimental therapies for restoring or repairing brain functions in neural conditions often involve changing or silencing hyperactive brain circuits explains Professor Guigliano. This can be done with medicines, gene therapy, or electrical or magnetic techniques to affect the brain. However all of these come with serious drawbacks. They unnaturally try and control these neurons. Our idea is to control ions, the very substances that the brain normally uses to function. Through this we’ll be able to discover and test new treatments for epilepsy.
Source Epilepsy Action

Glaring Employment Gap For People With Epilepsy Exposed

People with epilepsy face a glaring employment gap according to recent government figures highlighted by Epilepsy Action. Statistics show that as much as 66% of working age people with epilepsy are not in work. This has prompted Epilepsy Action to call for fairer access to, and treatment in, the workplace.
The employment rate for people with epilepsy is far lower than for people with most other disabilities, according to data from the Office for National Statistics. The rate for people with epilepsy as their main condition is 34% compared to 53% for people with disabilities generally. This is compared to an employment rate of 81% for those without a disability. Research by the Trade Union Congress (T.U.C.) has also highlighted that people with epilepsy in work are paid on average 11.8% less than non disabled workers.
Some people with epilepsy are unable to work at all. But depending on how epilepsy affects their daily life many people can work with minimal adjustments. Despite this they commonly report experiencing hurdles when applying for jobs or within the workplace. They say that disclosing their epilepsy at interviews can have a negative impact on their application. Many talk about experiencing discrimination from their employer or colleagues.
In a recent Institute of Employment Studies report, employers admitted they were reluctant to hire people with epilepsy largely due to safety concerns.
To access the Epilepsy Action toolkit for businesses to support their staff with epilepsy, visit
Source Epilepsy Action